First phase I clinical trial of an HIV-1 subtype D gp140 envelope protein vaccine: Immune activity induced in all study participants

AIDS

Volumn 22, Issue 1, 2008, Pages 149-151

  Hurwitz, Julia L ^a,b   Lockey, Timothy D ^a   Jones, Bart ^a   Freiden, Pamela ^a   Sealy, Robert ^a   Coleman, John ^a   Howlett, Nanna ^a   Branum, Kristen ^a   Slobod, Karen S ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT DNA; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOREACTIVITY; INJECTION SITE SWELLING; INJECTION SITE WARMTH; MALAISE; MYALGIA; NAUSEA; NUCLEOTIDE SEQUENCE; PAIN; PRIORITY JOURNAL; VACCINIA VIRUS;

ADULT; AIDS VACCINES; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; HEADACHE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION; IMMUNIZATION SCHEDULE; INJECTIONS, INTRAMUSCULAR; MALE; RECOMBINANT PROTEINS;

EID: 37349087164     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282f174ed     Document Type: Article

References (12)

1. Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse transcriptase. Science 1988; 242:1168-1171.
2. Koff RS. Immunogenicity of hepatitis B vaccines: implications of immune memory. Vaccine 2002; 20:3695-3701.
3. Ackers ML, Parekh B, Evans TG, Berman P, Phillips S, Allen M, et al. Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients. J Infect Dis 2003; 187:879-886.
4. Weber J, Fenyo EM, Beddows S, Kaleebu P, Bjorndal A. Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization. J Virol 1996; 70:7827-7832.
5. Moore JP, Cao Y, Leu J, Qin L, Korber B, Ho DD. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol 1996; 70:427-444.
6. Stambas J, Brown SA, Gutierrez A, Sealy R, Yue W, Jones B, et al. Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy. Vaccine 2005; 23:2454-2464.
7. Hurwitz JL, Zhan X, Brown SA, Bonsignori M, Stambas J, Lockey TD, et al. HIV-1 vaccine development: tackling virus diversity with a multienvelope cocktail. Front Biosci 2008; 13:609-620.
8. Caver TE, Lockey TD, Srinivas RV, Webster RG, Hurwitz JL. A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation. Vaccine 1999; 17:1567-1572.
9. Hurwitz JL, Slobod KS, Lockey TD, Wang S, Chou TH, Lu S. Application of the polyvalent approach to HIV-1 vaccine development. Curr Drug Targets Infect Disord 2005; 5:143-156.
10. Richmond JFL, Mustafa F, Lu S, Santoro JC, Weng J, O'Connell M, et al. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting. Virology 1997; 230:265-274.
11. Slobod KS, Lockey TD, Howlett N, Srinivas RV, Rencher SD, Freiden RJ, et al. Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1. Eur J Clin Microbiol Infect Dis 2004; 23:106-110.
12. Zhan X, Martin LN, Slobod KS, Coleclough C, Lockey TD, Brown SA, et al. Multienvelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV. Vaccine 2005; 23:5306-5320.